zeneca submitted approval new drug likely affect profits growth within two three years casodex treatment prostate cancer estimated lehman brothers stockbrokers potential sales dollars 250m dollars 500m pounds 323m year that would make zenecas thirdbiggest seller the drug oral antiandrogen about 300000 new prostate cancer cases reported year worldwide making second common cancer men approval drug sought first uk submissions regulatory authorities rest european union us follow end year likely reach market 1995 other companies making developing antiandrogens include schering plough johnson johnson us casodexs approval would place zeneca firmly cancer market it already nolvadex zoladex area outsold heart treatments zestril tenormin